PPARγ agonist 16, identified by its CAS number 2218046-01-4, is a synthetic compound that acts as an agonist for the peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ is a type of nuclear receptor that plays a crucial role in regulating glucose metabolism, lipid storage, and adipocyte differentiation. Compounds that activate PPARγ are of significant interest in the treatment of metabolic disorders, including type 2 diabetes and obesity, as they can enhance insulin sensitivity and promote fat cell differentiation. The characteristics of PPARγ agonist 16 include its potential to modulate gene expression involved in metabolic pathways, its ability to influence inflammatory responses, and its role in lipid metabolism. Additionally, like other PPARγ agonists, it may exhibit side effects related to fluid retention and weight gain, which are important considerations in therapeutic applications. Research into this compound continues to explore its efficacy, safety profile, and potential applications in metabolic disease management.

PPARγ agonist 16

2218046-01-4: PPARγ agonist 16, identified by its CAS number 2218046-01-4, is a synthetic compound that acts as an agonist for the peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ is a type of nuclear receptor that plays a crucial role in regulating glucose metabolism, lipid storage, and adipocyte differentiation. Compounds that activate PPARγ are of significant interest in the treatment of metabolic disorders, including type 2 diabetes and obesity, as they can enhance insulin sensitivity and promote fat cell differentiation. The characteristics of PPARγ agonist 16 include its potential to modulate gene expression involved in metabolic pathways, its ability to influence inflammatory responses, and its role in lipid metabolism. Additionally, like other PPARγ agonists, it may exhibit side effects related to fluid retention and weight gain, which are important considerations in therapeutic applications. Research into this compound continues to explore its efficacy, safety profile, and potential applications in metabolic disease management.

PPARγ agonist16 (Compound 4G) is a PPARγ agonist that competitively binds to the ligand-binding domain (LBD) of PPARγ with an IC50 of 1790 nM. It reduces ear swelling in mouse models and exhibits antihyperglycemic activity in mice with Streptozotocin-induced diabetes.

CAS 2218046-01-4

PPARγ agonist 16

PPARγ agonist 16

Ref: TM-T203519